Marso 2016 — SUSTAIN-6 CVOT Semaglutide

New England Journal of Medicine

Marso SP, et al.

Summary

26% reduction in MACE

Study Details

Study Design

Phase 3 double-blind CVOT

Indication

CV outcomes in T2D

Intervention

Semaglutide 0.5/1.0 mg weekly

Species

Human

Sample Size

3,297 subjects